Immune Thrombocytopenia (ITP)
32
15
15
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
6.3%
2 terminated out of 32 trials
75.0%
-11.5% vs benchmark
9%
3 trials in Phase 3/4
67%
4 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (32)
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)
V-IMMUNE® for Immune Thrombocytopenia
A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders
An Exploratory Study of Golidocitinib in Adult Patients With ITP
A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke
Longitudinal Observational Study on Immune Thrombocytopenia
Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
Level of Serum Lactate Dehydrogenase in Immune Thrombocytopenia